Milbank secured an important victory in the US Court of Appeals for the Federal Circuit on behalf of Orexo AB and Orexo US, Inc., in a patent infringement lawsuit against Actavis relating to patents that cover Orexo’s flagship Zubsolv® product. Zubsolv® is a sublingual tablet that is used to treat opioid addiction. As a result of the Court decision, Orexo has secured patent protection for Zubsolv® through patent expiration in 2032.
Milbank’s Intellectual Property Litigation & Technology team, led by partners Errol Taylor and Fred Zullow as well as associates Anna Brook and Jordan Markham, were featured as “Legal Lions” by Law360 for persuading the US Court of Appeals for the Federal Circuit to overturn a ruling from a bench trial in Delaware federal court.
The American Lawyer also named Errol Taylor as runner-up for Litigator of the Week, citing that Orexo’s stock price “nearly doubled” when news broke of the win.
